share_log

Altimmune | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-STATE STREET CORPORATION(5.51%)

Altimmune | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-STATE STREET CORPORATION(5.51%)

Altimmune | SC 13G/A：超過5%持股股東披露文件(修正)-STATE STREET CORPORATION(5.51%)
美股sec公告 ·  07/10 18:39
牛牛AI助理已提取核心訊息
State Street Corporation, a financial services and bank holding company headquartered in Boston, Massachusetts, has filed an amended Schedule 13G with the United States Securities and Exchange Commission (SEC) on June 30, 2024, indicating a significant ownership stake in Altimmune Inc., a biopharmaceutical company. According to the filing, State Street Corporation has shared voting power over 3,667,576 shares and shared dispositive power over 3,909,286 shares of Altimmune's common stock. The filing asserts that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of Altimmune Inc. The subsidiaries of State Street Corporation listed in the filing as beneficial owners of the securities include SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, State Street Global Advisors Limited, and State Street Global Advisors Trust Company, all classified as investment advisors (IA).
State Street Corporation, a financial services and bank holding company headquartered in Boston, Massachusetts, has filed an amended Schedule 13G with the United States Securities and Exchange Commission (SEC) on June 30, 2024, indicating a significant ownership stake in Altimmune Inc., a biopharmaceutical company. According to the filing, State Street Corporation has shared voting power over 3,667,576 shares and shared dispositive power over 3,909,286 shares of Altimmune's common stock. The filing asserts that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of Altimmune Inc. The subsidiaries of State Street Corporation listed in the filing as beneficial owners of the securities include SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, State Street Global Advisors Limited, and State Street Global Advisors Trust Company, all classified as investment advisors (IA).
美國波士頓State Street Corporation，一家總部位於馬薩諸塞州的金融服務和銀行控股公司，在2024年6月30日向美國證券交易委員會（SEC）提交了修正後的13G表格，表明其在生物製藥公司Altimmune Inc.擁有重要持股。根據申報文件，State Street Corporation在Altimmune普通股中擁有3667576股的共同投票權和3909286股的共同支配權。申報文件聲明這些股份是在業務的正常過程中獲得的，而不是爲了改變或影響Altimmune Inc.的控制權。在文件中列出的State Street Corporation的子公司，作爲投資顧問（IA）...展開全部
美國波士頓State Street Corporation，一家總部位於馬薩諸塞州的金融服務和銀行控股公司，在2024年6月30日向美國證券交易委員會（SEC）提交了修正後的13G表格，表明其在生物製藥公司Altimmune Inc.擁有重要持股。根據申報文件，State Street Corporation在Altimmune普通股中擁有3667576股的共同投票權和3909286股的共同支配權。申報文件聲明這些股份是在業務的正常過程中獲得的，而不是爲了改變或影響Altimmune Inc.的控制權。在文件中列出的State Street Corporation的子公司，作爲投資顧問（IA）的有SSGA Funds Management，Inc.，State Street Global Advisors Europe Limited，State Street Global Advisors Limited和State Street Global Advisors Trust Company，均爲這些證券的有益所有人。

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。